We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
Eli Lilly
LLY
$1.02T
$26.3M 0.99%
177,637
-29,200
-14% -$4.52M
ZBH icon
27
Zimmer Biomet
ZBH
$18.2B
$26.1M 0.98%
197,695
+100,202
+103% +$13.1M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$27.5B
$25.5M 0.95%
174,894
+49,027
+39% +$6.97M
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$11.6B
$24.8M 0.93%
325,822
+80,460
+33% +$8.14M
EW icon
30
Edwards Lifesciences
EW
$49.6B
$23.2M 0.87%
291,155
+89,009
+44% +$6.95M
CVS icon
31
CVS Health
CVS
$133B
$22.7M 0.85%
388,263
-331,357
-46% -$20.6M
STE icon
32
Steris
STE
$22.3B
$22.3M 0.84%
126,779
+115,561
+1,030% +$18.5M
WAT icon
33
Waters Corp
WAT
$37B
$21.4M 0.8%
109,510
+72,326
+195% +$15M
ASND icon
34
Ascendis Pharma A/S
ASND
$16B
$19.4M 0.73%
125,746
+68,264
+119% +$9.81M
SNY icon
35
Sanofi
SNY
$103B
$19.2M 0.72%
381,920
+54,553
+17% +$2.81M
IMMU
36
DELISTED
Immunomedics Inc
IMMU
$19M 0.71%
223,336
-273,767
-55% -$13.8M
AZN icon
37
AstraZeneca
AZN
$263B
$18.9M 0.71%
172,167
+54,768
+47% +$6.09M
XRAY icon
38
Dentsply Sirona
XRAY
$2.68B
$17.9M 0.67%
408,473
+247,186
+153% +$10.9M
ISRG icon
39
Intuitive Surgical
ISRG
$127B
$17.8M 0.67%
75,207
-24,810
-25% -$5.57M
RMD icon
40
ResMed
RMD
$30.6B
$16.6M 0.62%
97,069
+79,238
+444% +$14.6M
ARGX icon
41
argenx
ARGX
$53.4B
$16.2M 0.61%
61,687
+16,710
+37% +$4.02M
MCK icon
42
McKesson
MCK
$100B
$16M 0.6%
107,537
– –
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$15.8M 0.59%
170,018
+51,762
+44% +$3.99M
VTRS icon
44
Viatris
VTRS
$20.4B
$15M 0.56%
1,010,754
– –
DHR icon
45
Danaher
DHR
$137B
$14.5M 0.55%
76,216
-103,533
-58% -$18.4M
INCY icon
46
Incyte
INCY
$24.2B
$13.7M 0.51%
152,605
-172,448
-53% -$16.6M
IDXX icon
47
Idexx Laboratories
IDXX
$44.1B
$13.7M 0.51%
34,814
-2,200
-6% -$813K
LH icon
48
Labcorp
LH
$25B
$13.2M 0.49%
81,483
+26,483
+48% +$4.2M
NVS icon
49
Novartis
NVS
$297B
$13.2M 0.49%
151,525
-19,483
-11% -$1.69M
GH icon
50
Guardant Health
GH
$21.7B
$13.2M 0.49%
117,852
+36,430
+45% +$3.33M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.